Recent developments in the use of chemotherapy in brain tumours

Martin J. Van Den Bent*, Monika E. Hegi, Roger Stupp

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

112 Scopus citations

Abstract

Several recent studies have further clarified the role of chemotherapy in newly diagnosed anaplastic glioma. For newly diagnosed glioblastoma, combined daily radiotherapy with daily temozolomide followed by six cycles of adjuvant temozolomide improves overall survival. This benefit is especially observed in patients with a methylated promotor of the MGMT gene which encodes an alkyltransferase; this observation however, needs confirmation. Although oligodendroglial tumours are sensitive to chemotherapy, classical adjuvant nitrosourea-based chemotherapy does not improve overall survival in newly diagnosed anaplastic oligodendroglioma, even in the subset of 1p/19q loss tumours. It may increase progression-free survival however, and further studies must show if combined modality treatment with daily chemotherapy during radiotherapy increases survival. Trials exploring the role of chemotherapy in low-grade glioma are ongoing. No standard chemotherapy is currently available for highly anaplastic glioma failing first-line temozolomide-based therapy.

Original languageEnglish (US)
Pages (from-to)582-588
Number of pages7
JournalEuropean Journal of Cancer
Volume42
Issue number5
DOIs
StatePublished - Mar 2006

Keywords

  • Anaplastic glioma
  • Glioblastoma
  • MGMT
  • Oligodendroglioma
  • PCV
  • Radiotherapy
  • Temozolomide

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Recent developments in the use of chemotherapy in brain tumours'. Together they form a unique fingerprint.

Cite this